# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developersCharles Ri...
This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of Fib...
GMP grade plasmid DNA to serve as a direct therapeutic targeting various indicationsCharles River Laboratories International, I...
Argus Research analyst David Toung maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $200 to $290.
Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE:CR...